secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001104659-25-109158
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Passage Bio Q3 net loss $7.7M; cash runway into 1Q 2027; FTD trial enrollment ongoing
--------------------------------------------------------------------------------

- Cash and marketable securities $52.8M as of Sep 30, 2025; expected to fund operations into 1Q 2027.
- Net loss narrowed to $7.7M ($2.44 per share) vs $19.3M ($6.15) in Q3 2024; R&D and G&A expenses declined.
- Enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) in upliFT-D study; interim data expected in 1H 2026.
- Aligned with FDA on analytical comparability plan for suspension-based PBFT02 manufacturing process.
- On track for FDA feedback on FTD-GRN registrational trial design in 1H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000110465925109158/0001104659-25-109158-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000110465925109158/pasg-20251110x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-109158

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer